About Tirzepatide Tablet Review

This site is a verification ledger for the GLP-1 telehealth market: a public dataset of who charges what, with a status and a source on every figure, and a research library built on primary evidence. It is owned by Nash LLC, it earns commissions from provider links including a disclosed partnership with NexLife, and it is engineered so that neither fact can bend a number — the whole architecture of statuses, open dataset, and public corrections exists to make our incentives auditable rather than merely declared.

The people and the process

Research and pricing work is done by the site's research team: dataset maintenance, checkout verification walks, source cataloging, and the writing itself, which follows the standards in our editorial policy — primary sources, statuses on every price, no fabricated scores, and a hard rule against averaging away conflicts. Medical review is performed by Dr. A. Goher, MD (MBBS, Xi'an Jiaotong University, 2017), whose three-step review covers clinical accuracy, evidence-citation fidelity, and safety-language completeness; the review is per-article, and — the part we're strict about — the "medically reviewed" badge appears only on articles where that specific review is complete, with everything else labeled "pending clinician sign-off." A pending badge on a live article isn't an embarrassment here; it's the system telling you the truth about where the process stands.

How the money works

Outbound links to providers may pay commissions; NexLife's relationship is a disclosed material connection under FTC 16 CFR Part 255, detailed with the ownership structure on the ownership page. Three structural rules govern the conflict: NexLife's figures wear the operator-supplied label until independently verified, exactly like any operator's claims; rankings and the quiz compute from the public dataset, which anyone can download and re-rank; and the review-consensus page flags rankings that favor our partner with more scrutiny, not less — including external sites we cannot verify. If we ever fail those rules, the corrections log is where the failure and the fix will be public.

What this site is not

Not medical advice — the library explains evidence and mechanics so your clinician conversations are better, and every dosing, switching, or stopping decision on these pages ends at a prescriber. Not a pharmacy, not a provider, and not a seller of anything except its own referrals, disclosed. Not neutral in the fake sense — we have a commercial partner and say so — but neutral in the checkable sense: same statuses, same dataset, same corrections standard for everyone. Contact, corrections, and topic requests: research@tirzepatidetabletreview.com or the corrections page — reader reports have already changed the dataset, and the 48-hour clock applies to everyone, including us.